Please login to the form below

SAR302503

This page shows the latest SAR302503 news and features for those working in and with pharma, biotech and healthcare.

Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.

Latest news

Sanofi pulls development of blood cancer drug

The France-based pharma company said the reason to pull fedratinib – also known as SAR302503 – was due to the drug's link to an increased risk of the brain disorder
Jakavi shows long-term survival benefit in myelofibrosis

Meanwhile, Jakavi will have the market to itself for at least as a couple of years, as rival JAK inhibitors such as Sanofi's SAR302503 and Gilead Sciences' CYT387 are still
Sanofi plans to file JAK2 inhibitor after positive phase III

Sanofi has started to prepare for regulatory filings of its blood cancer treatment SAR302503 following positive results in a pivotal study. ... In the trial, patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythaemia vera
Sanofi has 65 new compounds in development, says R&D chief

Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed
Gilead expands in cancer with $510m YM BioSciences deal

Aside from Jakafi, other JAK inhibitors being developed for myelofibrosis include Sanofi's selective JAK2 inhibitor SAR302503 - phase II data for which were presented at ASH - and Cell Therapeutics Inc's

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Pharma deals during November 2013

While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Associate Director: £75, 000-90, 000

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Associate Editorial Director – Med Comms – London: Salary TBC

Medical Writers: Competitive Salary and Benefits

Senior Account Director development role to Business Director, H...: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Account Manager / Account Director: Competative

Director, Market Access / HEOR - North-West: Negotiable

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Medical/ Scientific Director: Salary TBC

Account Manager- Healthcare Advertising: Negotiable

Healthcare Communications Account Directors x 2: Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Associate Medical Director: Excellent PTO, bonus and 401k package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

New Business Director - PR: Competitive Salary and benefits

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Subscribe to our email news alerts

PMHub

Add my company

90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

A reflection of ESMO: Client Relationship Director Fabienne Wild from Ashfield Meetings & Events reflects on the recent conference season and on her experience at the European Society for Medical Oncology (ESMO)....
OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....